香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 China Oral Industry Group Holdings Limited 中 國 口 腔 產 業 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8406) 須予披露交易 及 有關截至二零二二年十二月三十一日止年度之年度業績公告之補充公告 須予披露交易 深圳拓盛採購協議 於二零二二年十月十七日，本公司間接全資附屬公司深圳金軒鼎（作為買方）與獨立第三方深圳拓 盛（作為賣方）訂立深圳拓盛採購協議，以總代價人民幣13.42百萬元（含增值稅）購買若干口腔護理 相關設備。 工商銀行金融產品 於二零二二年度，本公司間接全資附屬公司中山新宏達認購工商銀行金融產品，為工商銀行發行 的無固定期限理財產品。工商銀行金融產品於二零二二年十二月三十一日的公平值總額約為人民 幣30.1百萬元。 ...

Financial Performance - The company reported revenue of RMB 62,046 thousand for the three months ended March 31, 2023, a decrease of 20.3% compared to RMB 77,746 thousand in the same period of 2022[4]. - Gross profit for the same period was RMB 8,718 thousand, down 9.7% from RMB 9,651 thousand year-over-year[4]. - The company incurred a loss before tax of RMB 815 thousand, an improvement from a loss of RMB 1,131 thousand in the previous year[4]. - The net loss for the period was RMB 1,024 thousand, compared to a net loss of RMB 1,490 thousand in the same period last year, indicating a 31.2% reduction in losses[4]. - The company reported a total comprehensive loss of RMB 1,316 thousand for the period, compared to RMB 1,835 thousand in the same period last year, reflecting a 28.4% improvement[4]. - The basic and diluted loss per share was RMB 0.11, an improvement from RMB 0.19 in the previous year[4]. - The company's revenue for the first quarter of 2023 was approximately RMB 62,046,000, a decrease of about RMB 15,700,000 or 20.2% compared to RMB 77,746,000 in the same period of 2022[25]. - Revenue from inflatable amusement products was approximately RMB 58,304,000, down RMB 16,766,000 or 22.3% year-on-year, accounting for about 94.0% of total revenue[25]. - The gross profit for the period was approximately RMB 8,718,000, a decrease of about RMB 933,000 from RMB 9,651,000 in the same period of 2022, with a gross margin of 14.1%[29]. - The company recorded a loss of approximately RMB 1,024,000 for the period, a reduction of 31.3% compared to a loss of RMB 1,490,000 in the same period of 2022[34]. - The cost of sales was approximately RMB 53,328,000, a decrease of about RMB 14,767,000 or 21.7% compared to RMB 68,095,000 in the same period of 2022[27]. - Other income and gains totaled approximately RMB 321,000, a decrease of about RMB 68,000 or 17.5% compared to RMB 389,000 in the same period of 2022[30]. - Distribution and selling expenses amounted to approximately RMB 4,840,000, a decrease of about RMB 541,000 or 10.1% compared to RMB 5,381,000 in the same period of 2022[31]. - Administrative expenses were approximately RMB 4,685,000, a decrease of about RMB 670,000 or 12.5% compared to RMB 5,355,000 in the same period of 2022[32]. Revenue Sources - Revenue from the sale of inflatable products and related accessories was RMB 60,325 thousand, down 22.5% from RMB 77,786 thousand in the previous year[13]. - Revenue from dental clinic services amounted to RMB 1,720 thousand, which was not reported in the previous year[13]. - Revenue from North America increased significantly to RMB 50,541 thousand, up 34.8% from RMB 37,511 thousand in the same period of 2022[15]. Corporate Governance - The company did not recommend the payment of any interim dividend for the period[22]. - As of March 31, 2023, Risen Thrive Limited holds 424,560,000 shares, representing 44.23% of the company's total issued shares of 960,000,000[39]. - Ms. Yan Ping is the beneficial owner of all issued shares of Risen Thrive Limited and is considered to hold rights to all shares held by the company[40]. - No other individuals or entities hold 5% or more of the company's issued share capital as of March 31, 2023[42]. - The company has not granted any stock options under the stock option plan since its adoption on November 15, 2017[44]. - The company has complied with the corporate governance code as per GEM Listing Rules during the reporting period[49]. - The Audit Committee, established on June 20, 2017, has reviewed the unaudited financial results and confirmed compliance with applicable accounting standards[50]. - There were no purchases, sales, or redemptions of the company's listed securities during the reporting period[47]. - The company has not disclosed any changes in the information of directors or key executives that require disclosure under GEM Listing Rules[43]. - The company has confirmed that all directors complied with the trading standards during the reporting period[46]. - The Audit Committee includes independent non-executive directors with appropriate professional qualifications or financial management expertise[50]. Acquisitions - The company completed the acquisition of HongKong Eko Holding Co., Limited in January 2023, which is expected to provide new revenue sources in the dental care industry[24].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 China Oral Industry Group Holdings Limited 中 國 口 腔 產 業 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8406) 截至二零二三年三月三十一日止三個月 第一季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司可能 帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後 方作出投資決定。 由於GEM上市公司一般為中小型公司，於GEM買賣的證券可能會較於主板買賣的證券承受較大的市 場波動風險，同時無法保證於GEM買賣的證券會有高流通量的市場。 本公告之資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關中國口腔產 業集團控股有限公司（「本公司」及連同其附屬公司，統稱為「本集團 ...

Financial Performance - The total revenue for the year ended December 31, 2022, was approximately RMB 212,519,000, a decrease of about RMB 82,398,000 compared to RMB 294,917,000 in 2021, representing a decline of approximately 27.9%[12] - The loss for the year was approximately RMB 34,851,000, an increase of about RMB 32,718,000 or 1,533.9% compared to a loss of RMB 2,133,000 in 2021[12] - Gross profit for the year was approximately RMB 17,571,000, a decrease of about RMB 42,286,000 from RMB 59,857,000 in the previous year, resulting in a gross margin of 8.3%, down approximately 12% from 20.3%[25] - Other income and gains totaled approximately RMB 8,813,000, an increase of about RMB 6,603,000 or 298.8% compared to RMB 2,210,000 in the previous year[26] - Distribution and selling expenses amounted to approximately RMB 23,461,000, a decrease of about RMB 8,192,000 or 25.9% from RMB 31,653,000 in the previous year[27] - The company recorded impairment losses of approximately RMB 12,372,000 on property, plant, and equipment, an increase of about RMB 8,572,000 from RMB 3,800,000 in the previous year[33] - The group’s current ratio as of December 31, 2022, was approximately 2.83, compared to 2.58 as of December 31, 2021[36] - Capital expenditure for the year was approximately RMB 616,000, down from RMB 1,792,000 in the previous year[38] - The company recorded revenue from overseas customers of approximately RMB 202,544,000, accounting for 95.3% of total revenue, compared to 89.8% in the previous year[83] - Total revenue from the company's top five customers contributed approximately 60.8% of total revenue, up from 47.8% in the previous year[83] - The company has experienced a decline in revenue from overseas sales compared to the previous year, which was RMB 264,925,000[83] Business Strategy and Operations - The company plans to continue its inflatable products business in 2023 while further expanding into the health care industry, particularly in domestic oral care in China[13] - The company emphasizes maintaining high-quality standards for all products and aims to provide quality products for the oral care industry in the future[19] - The production base is located in Dongcheng Industrial Park, Zhongshan City, Guangdong Province, where the company manufactures its inflatable products[18] - The company has nearly 20 years of experience in designing, manufacturing, and selling high-quality inflatable amusement products and other inflatable products[18] - The company is committed to strict quality control procedures during the production process to enhance competitiveness through product differentiation and innovation[18] - The ongoing global pandemic has had varying degrees of impact on the company's main business operations[18] - The company plans to expand into medical and health-related services, including investments in dental clinics and health management service platforms[72] Shareholder and Investment Information - The company acknowledges the continued support from shareholders, customers, business partners, and suppliers[15] - The board of directors has confirmed the accuracy and completeness of the report's information after reasonable inquiries[3] - The group entered into an investment agreement to acquire the entire equity of a related company in the dental services sector, paying a deposit of RMB 13,000,000[43] - As of December 31, 2022, the company held significant investments in non-listed financial products amounting to RMB 30,899,000, with a fair value gain recognized in profit or loss of RMB 231,000 during the year[45] - The company did not hold any significant investments in 2021[46] - There are no major investment or capital asset plans for the upcoming year[47] Foreign Exchange and Credit Risk - Approximately 95% of the company's revenue for the year ended December 31, 2022, was denominated in USD, while production costs were in RMB, exposing the company to significant foreign exchange risk[48] - The company has not established any formal foreign exchange hedging policy or conducted hedging activities during the year due to cost-effectiveness considerations[48] - The company continues to face limited ability to mitigate foreign exchange risks due to the non-convertibility of the RMB[48] - The company maintains a policy of only engaging with customers that have suitable credit records to minimize credit risk[51] - The company recognized a credit loss provision for trade receivables of approximately RMB 547,000 for the year, compared to RMB 242,000 in the previous year[51] Employee and Compensation Information - The total employee compensation for the year ended December 31, 2022, was approximately RMB 50,993,000, down from RMB 75,797,000 in 2021, with a reduction in full-time employees from 953 to 571[52] - The company has implemented training programs to enhance employee skills and knowledge, with an annual training plan tailored to departmental needs[53] - The compensation policy includes fixed components (base salary) and variable components (discretionary bonuses and other rewards), considering factors such as experience, responsibilities, individual performance, and overall market conditions[126] - The senior management's salary ranges include two individuals earning up to HKD 1,000,000, one earning between HKD 1,000,001 and HKD 1,500,000, and three others in unspecified ranges[124] Corporate Governance - The board consists of three independent non-executive directors, ensuring over one-third of the board is independent, with at least one possessing relevant financial expertise[150] - The board is responsible for monitoring financial performance and internal controls, emphasizing the importance of independent judgment in strategy and risk management[150] - The company is committed to maintaining high corporate governance standards, regularly reviewing policies and compliance with legal regulations[152] - The company has established a director independence assessment mechanism to enhance board effectiveness and protect shareholder interests[161] - The company has provided sufficient resources for all committees to fulfill their duties effectively[167] - The audit committee held 5 meetings during the year to review the company's annual performance, interim results, and internal control procedures[167] - The audit committee concluded that the consolidated financial statements for the year ended December 31, 2022, comply with applicable accounting standards and GEM listing rules[168] - The company has engaged an independent consultant to review its internal control system, including financial and operational monitoring[188] Board Composition and Diversity - The board consists of 6 members from China, with 2 male and 4 female directors[200] - There are 3 executive directors and 3 non-executive directors on the board[200] - The age distribution includes 4 directors aged 41-50 and 2 directors aged 51-60[200] - The board has diverse industry experience, with 4 members in business management, 1 in accounting and finance, and 1 in healthcare[200] - The nomination committee has reviewed the board composition and found it to be diverse in terms of gender, industry experience, and skills[200] Miscellaneous - The company made a charitable donation of RMB 50,000 during the year ended December 31, 2022, consistent with the previous year's donation[140] - The company confirmed compliance with the public float requirements as per GEM listing rules as of the report date[142] - All independent non-executive directors have confirmed their independence according to GEM listing rules[143] - The company's consolidated financial statements for the year ended December 31, 2022, were audited by Guo Wei CPA, who will be proposed for reappointment at the 2023 annual general meeting[144]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 China Oral Industry Group Holdings Limited 中 國 口 腔 產 業 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8406） 截至二零二二年十二月三十一日止年度之年度業績公告 中國口腔產業集團控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董事」）會（「董事 會」）謹此宣佈本公司及其附屬公司截至二零二二年十二月三十一日止年度的經審核年度業績。 本公告列載本公司二零二二年年度報告（「年報」）全文，符合聯交所GEM證券上市規則（「GEM上市 規則」）中有關年度業績初步公告附載資料的相關要求。載有GEM上市規則規定資料的年報的印刷版 本，將於適當時候以GEM上市規則所規定方式寄發予本公司股東。 承董事會命 中國口腔產業集團控股有限公司 主席兼執行董事 嚴萍 香港，二零二三年三月二十九日 於本公告日期，董事會包括執行董事 ...

Financial Performance - Revenue for the three months ended September 30, 2022, was RMB 38,594,000, a decrease of 49% compared to RMB 75,710,000 for the same period in 2021[4] - Gross profit for the nine months ended September 30, 2022, was RMB 20,894,000, down 57.6% from RMB 49,332,000 in the same period of 2021[4] - The company reported a loss before tax of RMB 7,765,000 for the nine months ended September 30, 2022, compared to a profit of RMB 13,704,000 in the same period of 2021[4] - The total comprehensive loss for the three months ended September 30, 2022, was RMB 2,980,000, compared to a comprehensive income of RMB 569,000 for the same period in 2021[4] - The company’s basic and diluted loss per share for the nine months ended September 30, 2022, was RMB 1.04, compared to earnings of RMB 1.26 per share in the same period of 2021[4] - The company's revenue for the nine months ended September 30, 2022, was approximately RMB 182,495,000, a decrease of about RMB 40,230,000 or 18.1% compared to RMB 222,726,000 in the same period of 2021[25] - Revenue from the sale of inflatable products and related accessories for the three months ended September 30, 2022, was RMB 38,605,000, down from RMB 75,710,000 in the same period of 2021, representing a decrease of approximately 48.9%[13] - The gross profit for the nine months ended September 30, 2022, was approximately RMB 20,894,000, a decrease of about RMB 28,438,000 or 57.7% compared to RMB 49,332,000 in the same period of 2021[28] - The gross margin for the three months ended September 30, 2022, was approximately 11.5%, down from 22.1% in the same period of 2021, reflecting a decrease of about 10.6 percentage points[28] - The company recorded a net loss attributable to owners of the company of RMB (8,347,000) for the nine months ended September 30, 2022, compared to a profit of RMB 10,077,000 in the same period of 2021[21] - The company reported a loss of approximately RMB 8,347,000 for the period, a decrease of about RMB 18,424,000 or 182.8% compared to a profit of RMB 10,077,000 in the corresponding period of 2021[34] Other Income and Expenses - Other income and gains for the three months ended September 30, 2022, increased to RMB 3,691,000 from RMB 320,000 in the same period of 2021[4] - Other income and gains totaled approximately RMB 7,454,000 for the nine months ended September 30, 2022, an increase of about RMB 8,526,000 or 795% compared to RMB 1,072,000 in the same period of 2021, primarily due to foreign exchange gains of RMB 5,055,000[30] - The company’s financing costs for the nine months ended September 30, 2022, were RMB 1,231,000, a decrease from RMB 1,480,000 in the same period of 2021[4] - Distribution and selling expenses for the nine months ended September 30, 2022, were approximately RMB 19,687,000, a decrease of about RMB 2,045,000 or 9.4% compared to RMB 21,732,000 in the same period of 2021[31] - Administrative expenses increased to approximately RMB 15,195,000 for the nine months ended September 30, 2022, up by about RMB 1,707,000 or 12.66% from RMB 13,488,000 in the same period of 2021[32] Equity and Dividends - The total equity attributable to owners of the company as of September 30, 2022, was RMB 114,147,000, down from RMB 121,906,000 as of January 1, 2022[5] - The company did not recommend any interim dividend for the nine months ended September 30, 2022, consistent with the previous year[22] - The board of directors did not recommend any interim dividend for the period, consistent with the previous year[35] Corporate Governance and Compliance - The audit committee, consisting of three independent non-executive directors, has reviewed the financial results and confirmed compliance with applicable accounting standards and GEM listing rules[50] - The company has adhered to the corporate governance code as per GEM listing rules during the period[49] Future Plans - The company plans to expand into healthcare services, including dental clinics and health management services[9] - The company plans to collaborate with local governments and professional organizations in the oral care industry to establish an innovative oral care service platform, aiming to drive future business performance[24] Shareholder Information - As of September 30, 2022, Ms. Yan Ping holds 424,560,000 shares, representing 53.07% of the company's ordinary shares[38] - The company has not granted any stock options under the stock option plan adopted on November 15, 2017, up to the report date[43] - The company did not engage in any purchases, sales, or redemptions of its securities during the period[46] Capital Raising Activities - On October 21, 2022, the company entered into a placement agreement to issue up to 160,000,000 new shares at a price of HKD 0.260 per share, representing approximately 16.67% of the enlarged issued share capital[47] - The net proceeds from the placement, after deducting expenses, are approximately HKD 40,520,000, intended for investment in potential dental clinics in Guangdong and for working capital[47] Investments and Acquisitions - There were no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures during the period, and no plans for major investments or capital assets as of September 30, 2022[36]

中期報告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他於聯交所上市的公司帶有較高投資風險的中小型公司提供一個上市的市 場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 由於GEM上市公司一般為中小型公司，於GEM買賣的證券可能會較於主板買賣的證券承受較大的市場波 動風險，同時無法保證於GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明， 並明確表示，概不對因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 本報告之資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關中國口腔產業集 團控股有限公司（前稱為合寶豐年控股有限公司）（「本公司」，連同其附屬公司，「本集團」）之資料；本公司 董事（「董事」）願就本報告共同及個別地承擔全部責任。董事在作出一切合理查詢後確認，就彼等所深知及 確信，本報告所載資料在各重要方面均準確完備，並無誤導或欺詐成分，且並無遺漏其他事項，足以令致 本報告或其所載任何陳述產生誤導。 1 ...

Financial Performance - The revenue for the first quarter of 2022 was RMB 77,746,000, representing a 23.2% increase from RMB 63,125,000 in the same period of 2021[4] - The gross profit for the first quarter of 2022 decreased to RMB 9,651,000, down 33.8% from RMB 14,486,000 in the previous year[4] - The loss before tax for the first quarter of 2022 was RMB 1,130,000, compared to a profit of RMB 4,947,000 in the first quarter of 2021[4] - The net loss for the first quarter of 2022 was RMB 1,490,000, a significant decline from a profit of RMB 3,835,000 in the same period last year[4] - The total comprehensive loss for the first quarter of 2022 was RMB 1,835,000, compared to a total comprehensive income of RMB 3,866,000 in the first quarter of 2021[4] - The basic and diluted loss per share for the first quarter of 2022 was RMB (0.23), compared to earnings of RMB 0.48 per share in the same period of 2021[4] - Revenue from inflatable amusement products was approximately RMB 75,070,000, representing a 37.1% increase from RMB 54,748,000 in the previous year, accounting for about 96.6% of total revenue[23] - The company reported a loss attributable to owners of approximately RMB (1,490,000) compared to a profit of RMB 3,835,000 in the same period last year[19] Costs and Expenses - The cost of sales for the first quarter of 2022 was RMB 68,095,000, which is an increase of 40.2% from RMB 48,639,000 in the same period of 2021[4] - The cost of sales increased to approximately RMB 68,095,000, up RMB 19,456,000 or 40.4% from RMB 48,639,000 in the prior year, primarily due to rising raw material costs and increased employee expenses[25] - Distribution and selling expenses rose to approximately RMB 5,381,000, an increase of RMB 837,000 or 18.4% from RMB 4,544,000 in the prior year[29] - Administrative expenses for the first quarter of 2022 were RMB 5,355,000, up from RMB 4,537,000 in the first quarter of 2021[4] - Administrative expenses were approximately RMB 5,355,000, up RMB 818,000 or 18.1% from RMB 4,537,000 in the previous year, primarily due to increased employee benefits[30] Foreign Exchange and Other Income - The company reported a foreign exchange loss of RMB 345,000 in the first quarter of 2022, compared to a gain of RMB 31,000 in the previous year[4] - Other income and gains totaled approximately RMB 389,000, an increase of RMB 360,000 compared to RMB 29,000 in the previous year, mainly due to RMB 300,000 from leasing non-woven fabric production lines[28] Corporate Governance - The board did not recommend any interim dividend during the period, consistent with the previous year[20] - The board of directors is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance group performance[42] - The audit committee, established on June 20, 2017, ensures compliance with applicable accounting standards and GEM listing rules, and has reviewed the unaudited financial results for the period[45] - The audit committee includes independent non-executive directors with appropriate professional qualifications or accounting expertise, ensuring compliance with GEM listing rules[45] - The board will continuously review and improve corporate governance practices to ensure proper regulation of business activities and decision-making processes[43] - The board of directors confirmed compliance with the trading standards and the company's code of conduct regarding securities transactions during the period[40] - The company has not reported any conflicts of interest involving directors and controlling shareholders during the period[39] Business Expansion Plans - The company plans to launch healthcare-related services, including dental clinics and health management platforms[10] - The company aims to expand its business in the oral care industry in China, focusing on maintaining high standards for all products[22] Share Options and Securities - The company has not granted any share options under the share option scheme since its adoption on November 15, 2017[38] - The company has not purchased, sold, or redeemed any of its listed securities during the period[41] - The company has adopted a share option scheme to provide additional incentives to eligible participants for their contributions[37]

香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司可能帶有較高投資風 險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司一般為中小型公司，於GEM買賣的證券可能會較於主板買賣的證券承受較大的市場波動風險，同時 無法保證於GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示，概不對因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告之資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關中國口腔產業集團控股有限公 司（前稱為合寶豐年控股有限公司）（「本公司」，連同其附屬公司，「本集團」）之資料；本公司董事（「董事」）願就本報告共 同及個別地承擔全部責任。董事在作出一切合理查詢後確認，就彼等所深知及確信，本報告所載資料在各重要方面均 準確完備，並無誤導或欺詐成分，且並無遺漏其他事項，足以令致本報告或其所載任何陳述產生誤導。 1 ...

Financial Performance - Revenue for the three months ended September 30, 2021, was RMB 75.71 million, a slight increase from RMB 74.12 million in the same period of 2020, representing a growth of 2.14%[4] - Gross profit for the nine months ended September 30, 2021, was RMB 49.33 million, down 14.67% from RMB 57.75 million in the same period of 2020[4] - The net profit for the three months ended September 30, 2021, was RMB 0.66 million, a decrease of 90.18% compared to RMB 6.71 million in the same period of 2020[4] - The total comprehensive income for the nine months ended September 30, 2021, was RMB 9.67 million, down 54.38% from RMB 21.17 million in the same period of 2020[4] - The company reported a basic and diluted earnings per share of RMB 0.08 for the three months ended September 30, 2021, compared to RMB 0.84 in the same period of 2020[4] - Total revenue for the nine months ended September 30, 2021, was approximately RMB 222.726 million, an increase of RMB 24.353 million or 12.3% compared to RMB 198.373 million for the same period in 2020[23] - Profit for the nine months ended September 30, 2021, was approximately RMB 10.077 million, a decrease of RMB 11.192 million or 52.6% compared to RMB 21.269 million for the same period in 2020[23] Expenses and Costs - The company incurred financing costs of RMB 1.48 million for the nine months ended September 30, 2021, down 21.43% from RMB 1.88 million in the same period of 2020[4] - Distribution and selling expenses for the three months ended September 30, 2021, were RMB 6.90 million, a decrease of 29.49% from RMB 9.80 million in the same period of 2020[4] - The sales cost for the period was approximately RMB 173,394,000, an increase of about RMB 32,766,000 or 23.3% compared to the same period in 2020[28] - Gross profit for the period was approximately RMB 49,332,000, a decrease of about RMB 8,413,000 or 14.6% compared to the same period in 2020, with a gross margin of approximately 22.1%, down 7.0% from 29.1% in 2020[29] - Distribution and selling expenses amounted to approximately RMB 21,732,000, an increase of about RMB 3,578,000 or 19.7% compared to the same period in 2020[31] - Administrative expenses were approximately RMB 13,488,000, an increase of about RMB 792,000 or 6.2% compared to the same period in 2020[32] Revenue Breakdown - Revenue from inflatable amusement products with blowers was approximately RMB 198.936 million, an increase of RMB 19.983 million or 11.2%, accounting for about 89.3% of total revenue[25] - Revenue from other inflatable products decreased by approximately RMB 854,000 or 45.0%, accounting for about 0.5% of total revenue[25] - Revenue from electronic solar products increased by approximately RMB 1.643 million or 22.7%, accounting for about 4.0% of total revenue[25] - Revenue from inflatable product-related accessories and subcontracting work increased by approximately RMB 3.581 million or 34.8%, accounting for about 6.2% of total revenue[25] Equity and Dividends - The total equity attributable to owners of the company as of September 30, 2021, was RMB 131.58 million, an increase from RMB 120.60 million as of September 30, 2020[5] - The company did not recommend any interim dividend for the nine months ended September 30, 2021[21] - The board did not recommend any interim dividend for the period[36] Other Financial Information - The company experienced a foreign exchange loss of RMB 0.09 million for the three months ended September 30, 2021, compared to a loss of RMB 0.90 million in the same period of 2020[4] - Other income and gains totaled approximately RMB 1,072,000, an increase of about RMB 468,000 or 77.5% compared to the same period in 2020[30] - Financing costs recorded interest on lease liabilities of approximately RMB 1,480,000, a decrease of about RMB 404,000 or 21.4% compared to the same period in 2020[33] - The company has not purchased, sold, or redeemed any of its securities during the period[45] - The audit committee reviewed the unaudited condensed consolidated financial results, ensuring compliance with applicable accounting standards and GEM listing rules[48] Future Outlook - The company aims to maintain stable sales growth and focus on technological improvements to reduce production costs despite challenges from rising material costs and transportation expenses in the fourth quarter of 2021 and next year[24] - The company has not disclosed specific future outlook or guidance in the provided content[4] Tax Information - The company’s Hong Kong profits tax rate is 16.5%, while its Chinese subsidiaries are subject to a 25% corporate income tax rate unless preferential rates apply[17]